Drugs / Acellular pertussis vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04793620 | Apr → Aug 2021 | pertussis | Adjuvance Technologies, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01529645 | Mar → Jul 2012 | diphtheria, pertussis, tetanus | Novartis Vaccines | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01267058 | Sep 1997 → Feb 1998 | diphtheria, pertussis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-10 | GlaxoSmithKline | Regulatory US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants gsk.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-10-10 | GlaxoSmithKline | US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acellular pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01529645 ↗ |
| Modality | Vaccine | “GSK Biologicals' acellular pertussis vaccine” NCT01267058 ↗ |
| Route | Intramuscular | “Intramuscular, single dose” NCT01267058 ↗ |